This article is more than 5 years old. Information may no longer be current.

Dextenza receives permanent J-code

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Dextenza has received a specific and permanent reimbursement J-code from the CMS, Ocular Therapeutix announced in a press release.

The code, J1096, will become effective Oct. 1.

Dextenza (dexamethasone ophthalmic insert 0.4 mg) is approved for the treatment of ocular inflammation and pain following ophthalmic surgery.

“We are pleased that CMS has issued a unique J-code for Dextenza and has done so one full quarter earlier than expected,” Antony Mattessich, Ocular Therapeutix president and CEO, said in the release. “Issuance of the J-code is important for the company as it now enables reimbursement in the office setting as well as in the surgical center, providing increased flexibility to physicians on how they use the product.”